NeoImmuneTech (950220) investor relations material

Executive summary

• Nine-month revenue was $4,485,593, driven by Endari sales, research services and a licensing-related equity payment; net loss was $8,290,002.

• Commercial Endari sales began in the U.S. in May 2026, alongside continued NT-I7 development across oncology, immune-reconstitution and acute radiation syndrome programs.

Financial highlights

• 9M revenue was $4,485,593 versus $39,666 in 9M 2025; gross profit was $4,059,228 after $426,365 cost of sales.

• 9M operating loss was $9,876,311 versus $13,518,849 in 9M 2025; net loss was $8,290,002 versus $14,921,232.

• Q3 revenue was $3,337,721, gross profit $2,997,739, operating loss $2,794,723 and net loss $2,839,066.

• 9M revenue included $2,794,490 net Endari sales, $1,090,370 licensing revenue and $600,733 service revenue. Endari billings of $4,061,610 included $1,267,120 in sales deductions.

Outlook and guidance

• NT-I7 strategy centers on acute radiation syndrome development and combination use with CAR-T; the ARS program is advancing through primate studies, with FDA and BARDA engagement and government procurement as goals.

• The NIT-126 CD19 CAR-T combination is in Phase 1b; a final clinical report is expected in December 2028, with Phase 2 planned subject to safety and efficacy results.

• NT-I7 licensing, partnerships and potential post-approval direct or partner sales remain commercialization routes; Endari market access is to be expanded, with an Authorized Generic launch planned to support competitiveness and profitability.